Bronchopulmonary Dysplasia in Premature Infants: Pathogenesis, Clinical Picture, Treatment and Prevention (Part 1)

V.I. Snysar, O.I. Obolonsky, D.M. Surkov, O.G. Kapustina, D.G. Volkov


The article describes the current views on the pathogenesis, clinical picture, diagnosis and treatment of bronchopulmonary dysplasia. Special attention is paid to the influence of ductus arteriosus on the occurrence and severity of bronchopulmonary dysplasia, to the mechanisms of the hemodynamic effects of patent ductus arteriosus on blood flow in the anterior cerebral artery, the vessels of the pulmonary circulation, the impact of patent duct on the development of pulmonary edema. Separately, the methods for closure of patent ductus arteriosus were considered. The advantages of pharmacologic ductal closure are noted.


bronchopulmonary dysplasia; pathogenesis; clinical picture; diagnosis; prevention; ductus arteriosus; cyclooxygenase inhibitors; premature newborns


Speer C.P. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia // Neonatology. — 2009. — Vol. 95. — P. 353-361.

Thomas W., Speer C.P. Nonventilatory strategies for prevention and treatmen of bronchopulmonary dysplasia — what is the evidence? // Neonatology. — 2008. — Vol. 94. — P. 150-159.

Fanaroff A.A., Stoll B.J., Wright L.L. et al. Trends in neonatal morbidity and mortality for very low birthweight infants// Am. J. Obstet. Gynecol. — 2007. — Vol. 196. — P. 147 e141-148.

Northway W.H. Jr, Rosan R.C., Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia // N. Engl. J. Med. — 1967. — Vol. 276. — P. 357-368.

Jobe A.H., Bancalari E. Bronchopulmonary dysplasia // Am. J. Respir. Crit. Care Med. — 2001. — Vol. 163. — P. 1723-1729.

Walsh M.C., Wilson-Costello D., Zadell A., Newman N., Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia // J. Perinatol. — 2003. — Vol. 23. — P. 451-456.

Walsh M.C., Yao Q., Gettner P. et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates // Pediatrics. — 2004. — Vol. 114. — P. 1305-1311.

Bancalari E., Gonzalez A. Clinical course and lung function abnormalities during development of neonatal chronic lung disease / Bland R.D., Coalson J.J. editors. // Chronic lung disease in early infancy. — New York: Marcel Dekker, 2000. — Р. 41-64.

Shennan A.T., Dunn M.S., Ohlsson A., Lennox K., Hoskins E.M. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period // Pediatrics. — 1988. — 82. — 527-532.

Van Marter L.J., Pagano M., Allred E.N., Leviton A., Kuban K.C. Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices // J. Pediatr. — 1992. — Vol. 120. — P. 938-946.

Stoll B.J., Hansen N.I., Bell E.F. et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network // Pediatrics. — 2010. — Vol. 126. — P. 443-456.

Thomas W., Speer C.O. Universitats-Kinderklinik Wurzberg / Bronchopulmonale Dysplasie Fruehgeborener Epidemiologie, Pathogenese und Therapie // Monatsschrift Kinderheilkd. — 2005. — 153. — 211-219.

Baraldi E., Filippone M. Chronic lung disease after premature birth // N. Engl. J. Med. — 2007. — Vol. 357. — P. 1946-1955.

Northway W.H. Jr. An introduction to bronchopulmonary dysplasia // Clin. Perinatol. — 1992. — Vol. 19. — P. 489-495.

Groneck P., Goetze-Speer B., Oppermann M., Eiffert H., Speer C. P. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates // Pediatrics. — 1994. — Vol. 93. — P. 712-718.

Speer C.P. Inflammation and bronchopulmonary dysplasia: A continuing story // Semin. Fetal. Neonatal. Med. — 2006. — Vol. 11. — P. 354-362.

May M., Marx A., Seidenspinner S., Speer C. P. Apoptosis and proliferation in lungs of human fetuses exposed to chorioamnionitis // Histopathol. — 2004. — Vol. 45. — P. 283-290.

May M., Strobel P., Preisshofen T., Seidenspinner S., Marx A., Speer C.P. Apoptosis and proliferation in lungs of ventilated and oxygen-treated preterm infants // Eur. Respir. J. — 2004. — Vol. 23. — P. 113-121.

Groneck P., Oppermann M., Speer C.P. Levels of complement anaphylatoxin C5a in pulmonary effluent fluid of infants at risk for chro­nic lung disease and effects of dexamethasone treatment // Pediatr. Res. — 1993. — Vol. 34. — P. 586-590.

Groneck P., Schmale J., Soditt V., Stuetzer H., Goetze-Speer B., Speer C. P. Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease // Pediatr. Pulmonol. — 2001. — Vol. 31. — P. 331-338.

Thomas W., Seidenspinner S., Kawczynska-Leda N., Chmielnicka-Kopaczyk M., Marx A., Wirbelauer J., Szymankiewicz M., Speer C.P. Clara cell secretory protein in tracheobronchial aspirates and umbilical cord serum of extremely premature infants with systemic inflammation // Neonatology. — 2010. — Vol. 97. — P. 228-234.

Thomas W., Seidenspinner S., Kawczynska-Leda N., Wirbelauer J., Szymankiewicz M., Speer C.P. Soluble receptor for advanced glycation end products (sRAGE) in tracheobronchial aspirate fluid and cord blood of very low birth weight infants with chorioamnionitis and funisitis // Early human development. — 2010. — Vol. 86. — P. 593-598.

Davis J.M. Superoxide dismutase: A role in the prevention of chronic lung disease // Biol. Neonate. — 1998. — Vol. 74, Suppl. 1. — P. 29-34.

Saugstad O.D. Oxidative stress in the newborn — a 30-year perspective // Biol. Neonate. — 2005. — Vol. 88. — P. 228-236.

Collard K.J., Godeck S., Holley J.E., Quinn M.W. Pulmonary antioxidant concentrations and oxidative damage in ventilated premature babies // Arch. Dis. Child. Fetal Neonatal. Ed. — 2004. — Vol. 89. — P. F412-416.

Thébaud B. Angiogenesis in lung development, injury and repair: Implications for chronic lung disease of prematurity// Neonatology. — 2007. — Vol. 91. — P. 291-297.

Thébaud B., Abman S. H. Bronchopulmonary dysplasia: Where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease // Am. J. Respir. Crit. Care Med. — 2007. — Vol. 175. — P. 978-985.

Jakkula M., Le Cras T.D., Gebb S., Hirth K.P., Tuder R.M., Voelkel N.F., Abman S.H. Inhibition of angiogenesis decreases alveolarization in the developing rat lung // Am. J. Physiol. — 2000. — Vol. 279. — P. L600-607.

Thébaud B., Ladha F., Michelakis E.D., Sawicka M., Thurston G., Eaton F., Hashimoto K., Harry G., Haromy A., Korbutt G., Archer S.L. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: Evidence that angiogenesis participates in alveolarization // Circulation. — 2005. — Vol. 112. — P. 2477-2486.

Bhatt A.J., Pryhuber G.S., Huyck H., Watkins R.H., Metlay L.A., Maniscalco W.M. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia // Am. J. Respir. Crit. Care Med. — 2001. — Vol. 164. — P. 1971-1980.

Thomas W., Seidenspinner S., Kramer B.W., Kawczynska-Leda N., Chmielnicka-Kopaczyk M., Marx A., Wirbelauer J., Szymankiewicz M., Speer C.P. Airway concentrations of angiopoietin-1 and endostatin in ventilated extremely premature infants are decreased after funisitis and unbalanced with bronchopulmonary dysplasia/death // Pediatr. Res. — 2009. — Vol. 65. — P. 468-473.

Thomas W., Seidenspinner S., Kramer B.W., Wirbelauer J., Kawczynska-Leda N., Szymankiewicz M., Speer C.P. Airway Angiopoietin-2 in ventilated very preterm infants: Association with prenatal factors and neonatal outcome // Pediatr. Pulmonol. — 2011. — Vol. 46. — P. 777-784.

Bose C., Van Marter L.J., Laughon M., O’Shea T.M., Allred E.N., Karna P., Ehrenkranz R.A., Boggess K., Leviton A. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation // Pediatrics. — 2009. — Vol. 124. — P. e450-458.

Hansen A.R., Barnes C.M., Folkman J., McElrath T.F. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia // J. Pediatr. — 2010. — Vol. 156. — P. 532-536.

Thébaud B., Lacaze-Masmonteil T. If your placenta doesn’t have it, chances are your lungs don’t have it either: The«Vascular hypothesis» Of bronchopulmonary dysplasia starts in utero // J. Pediatr. — 2010. — Vol. 156. — P. 521-523.

Stenmark K.R., Abman S.H. Lung vascular development: Implications for the pathogenesis of bronchopulmonary dysplasia // Ann. Rev. Physiol. — 2005. — Vol. 67. — P. 623-661.

Husain A.N., Siddiqui N.H., Stocker J.T. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia // Hum. Pathol. — 1998. — Vol. 29. — P. 710-717.

Coalson J.J. Pathology of bronchopulmonary dysplasia // Semin. Perinatol. — 2006. — Vol. 30. — P. 179-184.

Roberts D., Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth // Cochrane Database Syst. Rev. — 2006: CD004454.

Murphy K.E., Hannah M.E., Willan A.R., Hewson S.A., Ohlsson A., Kelly E.N., Matthews S.G., Saigal S., Asztalos E., Ross S., De­lisle M.F., Amankwah K., Guselle P., Gafni A., Lee S.K., Armson B.A. Multiple courses of antenatal corticosteroids for preterm birth (MACS): A randomised controlled trial // Lancet. — 2008. — Vol. 372. — P. 2143-2151.

Yost C.C., Soll R.F. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome // Cochrane Database Syst Rev. — 2000: CD001456.

Seger N., Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome // Cochrane Database Syst. Rev. — 2009: CD007836.

Bancalari E., Claure N., Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants // Biol. Neonate. — 2005. — Vol. 88. — P. 192-201.

Bose C.L., Laughon M.M. Patent ductus arteriosus: Lack of evidence for common treatments // Arch. Dis. Child Fetal. Neonatal. Ed. — 2007. — Vol. 92. — P. F498-502.

Schmidt B., Roberts R. S., Fanaroff A., Davis P., Kirpalani H.M., Nwaesei C., Vincer M. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: Further analyses from the trial of indomethacin prophylaxis in preterms (TIPP) // J. Pediatr. — 2006. — Vol. 148. — P. 730-734.

Schmidt B., Roberts R.S., Davis P., Doyle L.W., Barrington K.J., Ohlsson A., Solimano A., Tin W. Long-term effects of caffeine therapy for apnea of prematurity // N. Engl. J. Med. — 2007. — Vol. 357. — P. 1893-1902.

Evans N. Patent ductus arteriosus in the neonate // Current Paediatrics. — 2005. — 15(5). — 381-9.

Knight D.B. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials // Semin. Neonatol. — 2001. — 6. — 63-73.

Del Moral T., Claure N., Van Buskirk S., Bancalari E. Duration of patent ductus arteriosus as a risk factor for bronchopulmonary dysplasia // Pediatr. Res. — 2001. — 49. — 282-7.

Evans N., Archer L.N.J. Postnatal circulatory adaptation interm and healthy preterm neonates // Arch. Dis. Child. — 1990. — 65. — 24-6.

Skelton R., Evans N., Smythe J.A. Blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus // J. Paediatr. Child Health. — 1994. — 30. — 406-11.

Aranda J.V., Clyman R., Cox B. et al. A randomized, double-blind, placebocontrolled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants // Am. J. Perinatol. — 2009. — 26(3). — 235-45.

Crissinger K.D., Granger D.N. Characterization of intestinal collateral blood flow in the developing piglet // Pediatr. Res. — 1988. — 24. — 473-6.

Copyright (c) 2020 V.I. Snysar, O.I. Obolonsky, D.M. Surkov, O.G. Kapustina, D.G. Volkov

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта